Publication: Incidencia de osteonecrosis de los maxilares inducido por bifosfonatos post tratamiento implantológico
Loading...
Official URL
Full text at PDC
Publication Date
2013
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
Description
UCM subjects
Unesco subjects
Keywords
Citation
1. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cáncer. Cochrane Database Syst Rev. 2005 Jul 20; (3): CD003474.
2. Fleisch H. Bisphosphonates: Mechanisms of Action. Endocrine Reviews2009 19(1): 80–100.
3. http://www.segg.es/info_actualidad.asp?pag=1&cod=214(19/03/2013) Sociedad Española de Geriatría y Gerontología.
4. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005 Jul; 17 (4): 462-6.
5. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fracturesin postmenopausal
osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med.
1995 Nov 30; 333 (22):1437-43.
6. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of onceweekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005 Jun; 44 (6):813-8.
7. Morales A, Bachiller J. Bisfosfonatos en le enfermedad de Paget. En: Bisfosfonatos en las enfermedades del metabolismo óseo y mineral. Monografía de la Fundación Hispana de Osteoporosis y Enfermedades Metabólicas Óseas. Madrid. 2002. 4; 29-48.
8. Sosa M, Hernández D, Segarra MC. Bisfosfonatos en otras enfermedades/calcificaciones. En: Bisfosfonatos en las enfermedades del metabolismo óseo y mineral. Monografía de la Fundación Hispana de Osteoporosis y Enfermedades Metabólicas Óseas. Madrid. 2002. p. 107-12.
9. Camil Castelo-Branco Flores; Francisco Javier Haya Palazuelos. Osteoporosis y menopausia. Buenos Aires: Madrid; Editorial Medica Panamericana, 2009. 287.
10. Emérito Carlos Rodríguez Merchán, Miguel Ortega Andreu, Gustavo Alonso Carro. Fracturas osteoporóticas: prevención y tratamiento. Ed. Médica Panamericana, 2003. p. 22.
11. Shreyasee A. y revisado por la Comisión de Marketing y Comunicaciones del Colegio Estadounidense de Reumatología. Osteoporosis: American College Of Rheumatology. Jun. 2006.
12. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope. 2006 Jan; 116 (1):115-20.
13. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008 Jul 1; 113 (1):193-201.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. HORIZON Pivotal
Fracture Trial.Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl
J Med. 2007 May 3; 356 (18):1809-22.
15. Recker RR, Weinstein RS, Chesnut CH 3rd, Schimmer RC, Mahoney P, Hughes C, et al.
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with
postmenopausal osteoporosis: results from the BONE study.Osteoporos Int. 2004 Mar;
15(3):231-7.
16. Sharpe M, Noble S, Spencer MC. Alendronate. An update of its use in osteoporosis. Drugs
2001; 61 (7): 999-1039.
17. Dunn CJ, Goa KL. Risedronate. A review of its pharmacological properties and clinical use
in resorptive bone disease. Drugs. 2001; 61 (5): 685-712.
18. Ponte Fernández N, Estefania Fresco R, Aguirre Urizar JM. Bisphosphonates and oral
pathology I. General and preventive aspects. Med Oral Patol Oral Cir Bucal. 2006 Aug
1;11(5):E396-400.
19. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous
bisphosphonates. Ann Oncol. 2006 Jun; 17(6):897-907.
20. Rubegni P, Fimiani M. Images in clinical medicine. Bisphosphonateassociated contact
stomatitis. N Engl J Med. 2006 Nov 30; 355(22):25.
21. Riancho JA. Bisfosfonatos orales en el tratamiento de la osteoporosis. En: Riancho JA,
González J. Manual Práctico de osteoporosis y enfermedades del metabolismo mineral.
Santander. 2004; (34):183-6.
22. García E, Muñoz MJ, Honorato J. Bisfosfonatos: química y farmacocinética. En:
Bisfosfonatos en las enfermedades del metabolismo óseo y mineral. Monografía de la
Fundación Hispana de Osteoporosis y Enfermedades Metabólicas Óseas. . Madrid. FHOEMO
.2002. p.7-17.
23. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates
inhibit angiogenesis in vitro and testosteronestimulated vascular regrowth in the ventral prostate
in castrated rats. Cancer Res. 2002 Nov 15; 62 (22):6538-44.
24. Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Acil Y. Expression profile and synthesis of
different collagen types I, II, III, and human gingival fibroblasts, osteoblast, and SaOS2 cells
after bisphosphonate treatment. Clin Oral Invest. 2009 Jul 14. [Epub ahead of print]
25. Hansen T, Kunkel M, Weber A, James Kirkpatrick C. Osteonecrosis of the jaws in patients
treated with bisphosphonates histomorphologic analysis in comparison with infected
osteoradionecrosis. J Oral Pathol Med. 2006 Mar; 35 (3):155-60.
26. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg. 2008 Apr; 66(4):767-75.
27. Markiewicz MR, Margarone JE 3rd, Campbell JH, Aguirre A. Bisphosphonateassociated osteonecrosis of the jaws: a review of current knowledge. J Am Dent Assoc. 2005 Dec; 136
(12):1669-74.
28. Sosa M, Gómez de Tejada MJ, Bagán JV, Díaz M, Díez A, Jódar E, et al. Osteonecrosis of the Jaw. Rev Osteoporos Metab Miner. 2009; 1 (1): 41-51.
29. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology. 2006 Aug; 20(9):1053-62.
30. Silverman S. L., Landesberg R. Osteonecrosis of the Jaw and the Role of Bisphosphonates: A Critical Review. Am J Med. 2009; 122:S33–S45.
31. Kudravi SA, Reed MJ. Aging, cancer, and wound healing. In vivo. 2000 JanFeb; 14 (1):8392.
32. Junquera L, Gallego L. Non exposed bisphosphonaterelated osteonecrosisof the jaws: another clinical variant? J Oral Maxillofac Surg 2008; 66 (7):1516–7.
33. Sosa M, Castro R. Tratamiento de la osteoporosis. Metodología de su evaluación. An Med Interna. 2007; 24:53-56.
34. Sosa M, Travesí I, Castro R. Tratamiento de la osteoporosis. An Med Interna. 2007; 24:57-61.
35. Damato K, Gralow J, Hoff A, Huryn J, Marx R, Ruggiero S, y cols. ADA council on scientific affairs. Expert panel recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaws: June 2004.
36. Bagán JV, Margaix M, Sarrión G, Marzal C, Silvestre J. Cuadro clínico y diagnóstico de la osteonecrosis de los maxilares por bisfosfonatos. En: Bagán JV. Osteonecrosis de los maxilares por bisfosfonatos. Valencia. Medicina Oral SL. 2008. p. 41-52.
37. Ruggiero Salvatore L., Mehrotra B., Rosenberg T. J., Engroff S. L. Osteonecrosis of the Jaws Associated With the Use of Bisphosphonates: A Review of 63 Cases. J Oral Maxillofac Surg. 2004; 62(5):527-34.
38. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonateassociated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive
cancer therapy. Cancer. 2005 Jul 1; 104 (1):83-93.
39. Gómez Font R, Martínez García ML, Olmos Martínez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal. 2008 May 1; 13(5): E318-24.
40. Grant B. T., Amenedo C., Freeman K., Kraut R. A., Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg. Feb 2008; 66(2):223-30.
41. Paz Mínguez Serra M., Salort Llorca C., Silvestre Donat F. J. Oral implants in patients receiving bisphosphonates: A review and update. Med Oral Patol Oral Cir Bucal. Dec 2008; 13:E755-60.
42. Brett L. F. Bisphosphonate’s Effect on Bone Cell Survival and Healing. American Association of Oral and Maxillofacial Surgeons. Sep. 2007; 65:17.
43. Alons K., Kuijpers Sophie C.C., De Jong Edo, Van Merkesteyn J. P. R., Leiden. Treating low- and medium-potency bisphosphonate–related osteonecrosis of the jaws with a protocol for the treatment of chronic suppurative osteomyelitis: report of 7 cases. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2009; 107:1-7.
44. Abu-id M. H., Warnke P. H., Gottschalk J., Springer I., Wiltfang J., Acil Y., Russo P. A.J., Kreusch T. “Bis-phossy jaws” – High and low risk factors for bisphosphonate-induced
osteonecrosis of the jaw: Journal of Cranio-Maxillofacial Surgery 2008; 36:95-103.
45. Grbic J. T., Landesberg R., Lin Shou-Qing, Mesenbrink P., Reid Ian R., Leung Ping-Chung, Casas Noemi, Recknor Christopher P., Hua Ye, Delmas Pierre D., Eriksen Erik F. Incidence of Osteonecrosis of the Jaw in Women with Postmenopausal Osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial. The Journal of the American dental association 2008; 139:32-40.
46. Fung. E., Harper R. P. Bisphosphonate Related Osteonecrosis of the Jaws J Rheumatol. Feb 2009; 36(2):450 - 450.
47. Wang, H. L., Daniel Weber, Laurie K. McCauley. Effect of Long-Term Oral Bisphosphonates on Implant Wound Healing: Literature Review and a Case Report. Journal of Periodontology. 2007; 78:584-594.
48. Donoghue M. Bisphosphonates and osteonecrosis: analogy to phossy jaw. The Medical Journal of Australia. 2005; 183:163-4.
49. Hunter D. Occupational diseases. Lecture II. Phosphorus, mercury, silver, manganese, metal fume fever, nickel carbonyl, infections, anthrax, glanders, weils disease, ankylostomiasis, cysticercosis, deficiency diseases. Lond Hosp Gaz 1935; 39: 25-50.
50. Khosla S., Burr D., Cauley J., Dempster D. W., Ebeling P. R., Felsenberg D., Gagel R. F, Gilsanz V., Guise T., Koka S., McCauley L. K., McGowan J., McKee M. D., Mohla S., Pendrys D. G., Raisz L. G., Ruggiero Salvatore L., Shafer D. M., Shum L., Silverman S. L., Van Poznak Catherine H., Watts N., Woo Sook-Bin, Shane E. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J
Bone Miner Res. 2007; 22:1479–1491.
51. Mehrotra B., Ruggiero S. Bisphosphonate Complications Including Osteonecrosis of the Jaw. American Society of Hematology. 2006; 356-60.
52. Jaimes M., Duque de Miranda Chaves Netto H., Olate S.; das Graças A. Miranda Chaves M.; de Albergaria Barbosa J. R. Biphosphonate and Jaws Osteonecrosis. Considerations About of Treatment International Journal of Morphology Int. J. Morphol. 2008; 26:681-688.
53. Ferrés G. A. Efecto de Bifosfonatos de Uso Sistémico en Maxilares. Revista de la sociedad de endodoncia de Chile. Abr 2008; 17:4-5.
54. Bagán J., Blade J., Constela M., García Sanz R., Lahuerta J., Llunch A., Massuti B., San Miguel J. Recomendaciones para la prevención, Diagnóstico y Tratamiento de Osteonecrosis de los maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos: Consenso del panel español de expertos. Nov. 2006.
55. Acero J., Burgueño M., de Vicente J. C., Martín-Granizo R., Santamaría J., Infante P., Raspall G. y López Cedrún J. L. Diagnóstico, Prevención y Tratamiento de la Osteonecrosis de los Maxilares por Bisfosfonatos. Recomendaciones de la Sociedad Española de Cirugía Oral y
Maxilofacial (SECOM). J Oral Maxillofac Surg. 2005; 63:1567-75.
56. Fugazzotto P. A., Lightfoot W.S., Jaffin R., Kumar A. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices. J Periodontol. Sep 2007; 78:1664-9.
57. Leon A. A. Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies. J Oral Maxillofac Surg. 2009; 67:35-43.
58. Agencia Española de Medicamento Division de Farmacología y Farmacovigilancia. Bisfosfonatos de administración parental y osteonecrosis del maxilar: Comunicación sobre riesgos de medicamentos para profesional sanitarios. 8/11/2005.
59. Mulligan R, Sobel S. Osteoporosis: diagnostic testing, interpretation, and correlations with oral health--implications for dentistry. Dent Clin North Am. Apr 2005; 49:463-84.
60. American Association of Oral and Maxillofacial Surgeons. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and
Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65:369-76.
61. Beatrice J. E., John W. H., Jacobsen P. L., Kaltman S., Mariotti A., Migliorati C. A. Upºdated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2008; 139:1674-1677.
62. American Dental Association Council on Scientific Affairss. Dental management of patients receiving oral bisphosphonate therapy. J Am Dent Assoc. 2006; 137:1144-1150.
63. Bell B. M., Bell R. E. Oral Bisphosphonates and Dental Implants: A Retrospective Study. J Oral Maxillofac Surg. 2008; 66:1022-1024.
64. Starck W.J., Epker B.N. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants. Jan - Feb 1995; 10:74-8.
65. Scully C., Madrid C., Bagán J. Dental Endosseous Implants in Patients on Bisphosphonate Therapy. Implant dentistry. Oct 2006; 15:212-8.
66. Merigo E., Manfredi M., Meleti M., Corradi D., Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and
zoledronate): a four-case report. J Oral Pathol Med. Nov 2005; 34(10):613-7.
67. Marx R. E., Sawatari Y., Fortin M., Broumand V. Bisphosphonate-induced exposed bone
(osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. Nov 2005; 63:1567-75.
68. Ferrari S., Bianchi B., Savi A., Poli T., Multinu A., Balesteri A., Ferri A. Fibula free flap with endosseous implants for reconstructing a resected mandible in bisphosphonate osteonecrosis. J Oral Maxillofac Surg. 2008; 66:999-1003.
69. Goss A., Backhouse P. Bifosfonatos y osteonecrosis de la mandíbula. Aust Prescr. 2007; 30:96-7.
70. Aspenberg P. Bisphosphonates and implants. Acta Orthopaedica. Feb 2009; 80:119 – 123.
71. Torres J., Tamimi F., Garcia I., Herrero A., Rivera B., Sobrino J. A., Hernández G. Dental implants in a patient with Paget disease under bisphosphonate treatment: A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009; 107:387-392.
72. Barrientos Lezcano F. J., Peral Cagigal B., de la Peña Varela G., Sánchez Cuéllar L. A., García Cantera J. M., Serrat Soto A., Verrier Hernández A. Osteonecrosis de los maxilares inducida por bifosfonatos: prevención y actitud terapéutica. Rev. Esp. Cirug. Oral y Maxilofac.
Set. -Oct. 2007; 29:309-317.
73. Borba Reiriz A., De Zorzi P. de M.; Patrik Lovat C. Bifosfonatos y osteonecrosis de la mandíbula: reporte de un caso. Clinics. 2008; 63: 281-284.
74. Vassiliki M. C., Shao Z., Athanasios I. Z. Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714, 217 people. J Am Dent Assoc. Jan 2008; 139:23-30.
75. Purcell P. M., Boyd L. W. Bisphosphonates and osteonecrosis of the jaw. The Medical Journal of Australia. 2005; 182:417-8.
76. Carter G., Goss A. N., Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. The Medical Journal of Australia. 2005; 182:413-5.
77. Sarasquete M. E., García-Sanz R., Marín L., Alcoceba M., Chillón M. C., Balanzategui A., Santamaria C., Rosiñol L., de la Rubia J., Hernández M. T., Garcia-Navarro I., Lahuerta J. J., González M., San Miguel J. F. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood. Oct 2008; 112:2709-12.
78. Bilezikian P. J. Osteonecrosis of the Jaw — Do Bisphosphonates Pose a Risk? Nov 2006; 355:2278-2281.
79. Marx R. E. Reconstruction of Defects Caused by Bisphosphonate-Induced Osteonecrosis of the Jaws. J Oral Maxillofac Surg. 2009; 67:107-119.
80. Hellstein J., Marek C. Bisphosphonate osteochemonecrosis (Bis-phossy jaw): is this phossy
jaw of the 21st century. J Oral Maxillofac Surg. 2005; 63:682-9.
81. Olga Di Fede, Vittorio Fusco, Domenica Matranga, Luigi Solazzo, Mario Gabriele, Giovanni M. Gaeta, Gianfranco Favia, Delia Sprini, Franco Peluso, Giuseppe Colella Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multihospital-based study of 87 Italian cases European Journal of Internal Medicine, published online 14 June 2013.
82. Bagan JV, Diz Dios P, Gallego L, InfanteCossio P, Jiménez Y, Junquera LM, et al. Recomendaciones para la prevención de la osteonecrosis de los maxilares (ONM) en pacientes tratados con bisfosfonatos intravenosos. Med Oral Patol Oral Cir Bucal. 2008 May 1; 13(3): 161-7.
83. Bertó A, Miñana M, Miñana R: ONJ (Osteonecrosis de los maxilares relacionada con bifosfonatos). Guía para el tratamiento y prevención en endodoncia. Gaceta Dental. 2007 Mar; 179: 106-24.
84. Bagan JV, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recomendaciones para la prevención, diagnóstico y tratamiento de osteonecrosis de los
maxilares (ONM) en pacientes con cáncer tratados con bisfosfonatos Med Oral Patol oral Cir Bucal 2007; 12:279-83.
85. Bagan JV, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw
(ONJ) in cancer patients treated with bisphosphonates.Med Oral Patol Oral Cir Bucal. 2007 Aug 1; 12(4): E336-40.
86. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006 Feb 20; 24 (6): 945-52.
87. Agrillo A, Petrucci MT, Tedaldi M, Mustazza MC, Marino SM, Gallucci C, et al. New therapeutic protocol in the treatment of avascular necrosis of the jaws. J Craniofac Surg. 2006 Nov; 17(6):1080-3.
88. Junquera LM, MartínGranizo R. Diagnóstico, prevención y tratamiento de la osteonecrosis de los maxilares por bisfosfonatos. Recomendaciones de la sociedad española de cirugía oral y máxilofacial (SECOM). Rev ESp Oral y Maxilofac. 2008 May - Jun; 30 (3): 145-56.
89. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonateinduced osteonecrosis: risk factors,
prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg.
2007 Dec; 65 (12): 2397-410.
90. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007; 86 (11):1013–21.
91. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update. Oral Oncol. 2009 Feb 27. [Epub ahead of print]
92. Pérez SB, Barrero MV, Hernández MS, Knezevic M, Navarro JM, Millares JR. Osteonecrosis maxilar asociada al uso de bisfosfonatos. Una propuesta para el tratamiento
conservador. Med Oral Patol Oral Cir Bucal. 2009 Ener; 14 (1): 32-5.
93. Jimenez Y, Poveda R. Prevención de la osteonecrosis de los maxilares por bisfosfonatos. En: Bagán JV. Osteonecrosis de los maxilares por bisfosfonatos. 2008; 91-108.
94. American Academy of Oral and Maxillofacial Surgeons. Position paper on bisphosphonaterelated osteonecrosis of the jaws. Available at:
http://www.aaoms.org/docs/position_papers/osteonecrosis.pdf. Accessed December 11, 2006.
95. Bagán JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et al. Osteonecrosis of the jaws in intravenous bisphosphonate use: Proposal for modification of the clinical classification. Oral Oncol. 2008 Aug 18. [Epub ahead of print].
96. Carbonel E, Díaz JM, Murillo J. Tratamiento de la osteonecrosis de los maxilares por bisfosfonatos. En: Bagán JV. Osteonecrosis de los maxilares por bisfosfonatos. Valencia. Medicina Oral SL. 2008. p.71-90.
97. Diego R, D'Orto O, Pagani D, Agazzi A, Marzano U, Derada Troletti G, et al. Bisphosphonateassociated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar; 103(3):1-5.
98. Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, et al. Osteotomy and primary wound closure in bisphosphonateassociated osteonecrosis of the jaw: a
prospective clinical study with 12 months followup. Support Care Cancer. 2010 Apr; 18(4): 449-60.
99. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003. 61 (10): 1115-18.
100. Maerevoet M, Martin C, Duck L.Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul 7;353(1):99102; discussion 99102. Erratum in: N Engl J Med. 2005 Dec 22;
353(25):2728.
101. Yarom N, Elad S, Madrid C, Migliorati CA. Osteonecrosis of the jaws induced by drugs other than bisphosphonates a call to update terminology in light of new data. Oral Oncol. 2010 Jan; 46 (1):1.
102. Jaimes M, Oliveira GR, Olate S, Albergaria JR. Bifosfonatos asociado a osteonecrosis de los maxilares. Revisión de la literatura. Av. Odontoestomatol 2008; 24 (3): 219-226.
103. Heras Rincón I, Zubillaga Rodríguez I, Castrillo Tambay M, Montalvo Moreno JJ. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic
recommendations. Med Oral Patol Oral Cir Bucal 2007 Aug; 12 (4):267-71.
104. Escobar EA, López J, Marques MS, Chimenos E. Osteonecrosis de los maxilares asociada a Bifosfonatos: revisión sistemática. Av. Odontoestomatol. 2007; 23 (2): 91-101.
105. Bagán JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, et al. Avascular jaw
osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005 Feb; 34 (2):120-3.
106. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidente and risk factors. J Clin Oncol. 2005 Dec 1; 23 (34): 8580-7.
107. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates.N Engl J Med. 2005 Jul 7; 353(1):99-102.
108. Zarychanski R, Elphee E, Walton P, Johnston J.Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan; 81 (1): 73-5.
109. Schwartz HC. Osteonecrosis and bisphosphonates: correlation versus causation. J Oral Maxillofac Surg. 2004 Jun; 62(6):763-4.
110. Hoefert S, Schmitz I, Tannapfel A, Eufinger H. Importance of microcracks in etiology of bisphosphonaterelated osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and nonsymptomatic osteonecrosis of the jaw based on scanning electron microscopy findings. Clin Oral Investig. 2009 Jun 18. [Epub ahead of print]
111. Gavaldá C, Milián MA. Incidencia de la ONM en pacientes tratados con bisfosfonatos intravenosos. En: Bagán JV. Osteonecrosis de los maxilares por bisfosfonatos.Valencia. Medicina Oral SL. 2008. p. 25-32.
112. Dore F, Filippi L, Biasotto M, Chiandussi S, Cavalli F, Di Lenarda R. Bone scintigraphy and SPECT/CT of bisphosphonate-induced osteonecrosis of the jaw. J Nucl Med. 2009 Jan; 50 (1): 30-5.
113. Favia G, Pilolli GP, Maiorano E. Histologic and histomorphometric features of
bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone. 2009 Sep; 45(3):406-13.
114. Carmagnola D, Celestino S, Abati S. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Dec; 106 (6):10-5.
115. García-Sanz R, Alegre A, Capote FJ, Hernandez JM, Rosiñol L, De la Rubia J, et al. Utilización de bisfosfonatos en pacientes con mieloma multiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en
Hematología (GEM/PETHEMA). Medicina Clínica. 2010; 134 (6): 268-78.
116. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin
Proc. 2006 Aug; 81 (8):1047-53.
117. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2002; (3): CD003188.
118. Dimitrakopoulos I, Magopoulos C, Karakasis D. Bisphosphonateinduced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg. 2006 Jul; 35 (7):588-93.
119. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, et al. Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy.Oral Dis. 2005 Nov; 11(6):365-9.
120. Sanna G, Zampino MG, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with longterm use of biphosphonates. Ann Oncol. 2005 Jul; 16 (7):1207-8.
121. Estilo CL, Van Poznak CH, Williams T. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. J Clin Oncol. 2004; 22: 80-88.
122. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16; 144 (10):75361. Review. Erratum in:
Ann Intern Med. 2006 Aug 1; 145 (3):235.
123. Ruggiero SL, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006; 2:7-14.
124. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol. 2006 Aug; 17 (8):1197-204.
125. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC Jr. Bisphosphonates and jaw osteonecrosis: the UAMS experience.Otolaryngol Head Neck Surg. 2007 Mar; 136(3): 396-400.
126. Kos M, Kuebler JF, Luczak K, Engelke WBisphosphonaterelated osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg. 2010 Jun; 38(4):255-9.
127. Dannemann C, Grätz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone. 2007 Apr; 40(4): 828-34.
128. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing
factors and treatment outcome. Osteoporos Int. 2007 Oct; 18(10):1363-70.
129. Bagán JV, Jiménez Y, Murillo J, Hernández S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases.Oral Oncol. 2006 Mar; 42(3):327-9.
130. Estilo CL, Van Poznak CH, Wiliams T, Bohle GC, Lwin PT, Zhou Q, et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.Oncologist. 2008 Aug; 13(8): 911-20.
131. Bedogni A, Blandamura S, Lokmic Z, Palumbo C, Ragazzo M, Ferrari F, et al. Bisphosphonateassociated jawbone osteonecrosis: a correlation between imaging techniques
and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Mar; 105(3): 358-64.
132. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonateinduced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008 Sep; 44(9):85769.
133. Pazianas M, Blumentals WA, Miller PD. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int. 2008 Jun; 19 (6):773-9.
134. Yarom N, Elad S. Comment on Pazianas et al.: lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Osteoporos Int.
2008 Jun; 19(6):84950; author reply 851.
135. Malden N, Beltes C, Lopes V. Dental extractions and bisphosphonates: the assessment, consent and management, a proposed algorithm.Br Dent J. 2009 Jan 24; 206(2):93-8.
136. Bagan JV, Jiménez Y, Hernández S, Murillo J, Díaz JM, Poveda R, et al. Osteonecrosis of the jaws by intravenous bisphosphonates and osteoradionecrosis: a comparative study. Med Oral Patol Oral Cir Bucal. 2009 Dec 1; 14(12):616-9.
137. Salem AM, Zohny SF, Abd ElWahab MM, Hamdy R. Predictive value of osteocalcin and betaCrossLaps in metastatic breast cancer. Clin Biochem. 2007 Nov; 40 (1617): 1201-8.
138. Coleman R, Brown J, Terpos E, Lipton A, Smith MR, Cook R, et al. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008 Nov; 34 (7):629-39.
139. Schwartz HC. Serum CTX testing. J Oral Maxillofac Surg. 2008 Jun; 66 (6):131920; author reply 1320.
140. Lee C, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of
bisphosphonateassociated osteonecrosis of the jaws after surgery? Part II: A prospective clinical study. Implant Dentistry, 2010; 19(1): 29-35.
141. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw. Oral
bisphosphonateinduced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2008 Jun; 66 (6):1320-1; author reply 1321-2. Erratum in: J Oral Maxillofac Surg. 2008 Aug; 66 (8):1778.
142. Fantasia JE. Bisphosphonateswhat the dentist needs to know: practical considerations. J Oral Maxillofac Surg. 2009 May; 67(5):53-60.
143. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB. Managing the care of patients with bisphosphonate associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005 Dec; 136(12):165868. Review. Erratum in: J
Am Dent Assoc. 2006 Jan; 137(1):26.
144. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C.Biphosphonateassociated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Oct; 104 (4): 473-7.
145. Biasotto M, Chiandussi S, Dore F, Rinaldi A, Rizzardi C, Cavalli F, et al. Clinical aspects and management of bisphosphonate sassociated osteonecrosis of the jaws.Acta Odontol Scand. 2006 Nov; 64(6):348-54.
146. Etminan M, Aminzadeh K, Matthew IR, Brophy JM. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested casecontrol study. J Rheumatol. 2008 Apr; 35(4): 691-5.
147. Treister N, Sheehy N, Bae EH, Friedland B, Lerman M, Woo S. Dental panoramic radiographic evaluation in bisphosphonate associated osteonecrosis of the jaws. Oral Dis. 2009 Jan; 15 (1): 88-92.
148. Watts NB, Marciani RD. Osteonecrosis of the jaw. South Med J. 2008 Feb; 101(2):160-5.
149. Migliorati CA, Siegel MA, Elting LS.Bisphosphonateassociated osteonecrosis: a longterm
complication of bisphosphonate treatment. Lancet Oncol. 2006 Jun; 7(6):50814. Review. Erratum in: Lancet Oncol. 2006 Jul; 7(7): 533.
150. Cuevas MV, Martínez I, Fernández M, Zamora M, Álamo O. Osteonecrosis del maxilar en paciente con mieloma múltiple tratado con bisfosfonatos. Rev Electron Biomed/ Electron J
Biomed. 2006; 3:14-28.
151. Gallego L, Junquera L. Consequence of therapy discontinuation in bisphosphonateassociated osteonecrosis of the jaws. Br J Oral Maxillofac Surg. 2009 Jan;
47(1):67-8.
152. Del Conte A, Bernardeschi P, La Ferla F, Turrisi G, D'Alessandro M, Montagnani F, et al. Bisphosphonateinduced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma. J Oral Maxillofac Surg. 2010 May; 68 (5):1179-82.
153. Infante Cossío P, Cabezas Macián A, Pérez Ceballos JL, Palomino Nicas J, Gutiérrez Pérez JL. Bisphosphonaterelated osteonecrosis of the jaw in patients with multiple myeloma.
Med Oral Patol Oral Cir Bucal. 2008 Jan 1; 13(1): 52-7.
154. Pastor - Zuazaga D, GarateaCrelgo J, MartinoGorbea R, EtayoPérez A, SebastiánLópez C. Osteonecrosis of the jaws and bisphosphonates. Report of three cases.Med Oral Patol Oral Cir Bucal. 2006 Jan 1; 11 (1):76-9.
155. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc. 2005 Dec; 136 (12):1675-81.
156. Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonateinduced
osteonecrosis of the jaw in a patient with multiple myeloma.Int J Hematol. 2006 Nov; 84(4): 343-5.
157. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate associated osteonecrosis of the jaws with bone resection and autologous plateletderived growth factors. J Am Dent Assoc. 2007 Jul; 138(7): 971-7.
158. Lee CY, David T, Nishime M.Use of platelet-rich plasma in the management of oral biphosphonate - associated osteonecrosis of the jaw: a report of 2 cases. J Oral Implantol. 2007; 33 (6): 371-82.
159. Badr MS, Oliver RJ. Plateletrich plasma: an adjunctive treatment modality for bisphosphonate osteonecrosis? J Oral Maxillofac Surg. 2009 Jun; 67(6):1357.
160. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg. 2010 Mar; 39 (3):251-5.
161. Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian Association of Oral and Maxillofacial Surgeons. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol. 2008 Jul; 35(7):1391-7. Epub 2008 Jun 1. Erratum in: J Rheumatol. 2008 Aug; 35 (8):1688. J Rheumatol. 2008 Oct; 35(10):2084.
162. Estefanía R, Ponte R, Aguirre JM. Bisphosphonates and Oral pathology II. Osteonecrosis of the jaws: review of the literature before 2005. Med Oral Patol Oral Cir Bucal. 2006 Nov 1; 11 (6):456-61.
163. Siddiqi A, Payne AG, Zafar S. Bisphosphonateinduced osteonecrosis of the jaw: a medical enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Sep; 108 (3):18.
164. Hellstein JW, Marek CL. Bisphosphonate induced osteochemonecrosis of the jaws: an ounce of prevention may be worth a pound of cure. Spec Care Dentist. 2006 JanFeb; 26(1):8-12.
165. Van den Wyngaert T, Huizing MT, Fossion E, Vermorken JB. Bisphosphonates in oncology: rising stars or fallen heroes. Oncologist. 2009 Feb; 14 (2):181-91.
166. Marx RE, Stern DS. Biopsy principles and techniques. Oral and maxillofacial pathology: a rationale for diagnosis and treatment. Chicago: Quintessence, 2002. p. 36-8.
167. McLeod NM, Davies BJ, Brennan PA. Management of patients at risk of bisphosphonate osteonecrosis in maxillofacial surgery units in the UK. Surgeon. 2009 Feb; 7(1):18-23.
168. Beatrice J. E., John W. H., Jacobsen P. L., Kaltman S., Mariotti A., Migliorati C. A. Upºdated recommendations for managing the care of patients receiving oral bisphosphonate therapy: An advisory statement from the American Dental Association Council on Scientific
Affairs. J Am Dent Assoc. 2008; 139:1674-1677.
169. Marx RE. Uncovering the cause of "phossy jaw" Circa 1858 to 1906: oral and maxillofacial surgery closed case filescase closed. J Oral Maxillofac Surg. 2008 Nov; 66 (11): 2356-63.
170. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007 Mar; 65 (3):415-23.
171. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008 May; 42(5):841-7.
172. FlichyFernández AJ, BalaguerMartínez J, PeñarrochaDiago M, Bagán JV. Bisphosphonates and dental implants: current problems. Med Oral Patol Oral Cir Bucal. 2009 Jul 1; 14(7):355-60.
173. Montoya Carralero JM, Parra Mino P, Ramírez Fernández P, Morata Murcia IM, Mompeán Gambín Mdel C, Calvo Guirado JL. Dental implants in patients treated with oral
bisphosphonates: a bibliographic review. Med Oral Patol Oral Cir Bucal. 2009 Jan 1; 15(1):65-9.
174. Hwang D, Wang HL. Medical contraindications to implant therapy: Part II: Relative contraindications. Implant Dent. 2007 Mar; 16(1):13-23.
175. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twentynine cases. Acta Biomed. 2006 Aug; 77(2):109-17.
176. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants. 2006 MayJun; 21 (3):349-53.
177. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a singlecentre experience in 303 patients. Br J Haematol. 2006 Sep; 134 (6):620-3.
178. Longobardi G, Boniello R, Gasparini G, Pagano I, Pelo S. Surgical therapy for osteonecotic lesions of the jaws in patients in therapy with bisphosphonates. J Craniofac Surg. 2007 Sep; 18 (5):1012-7.
179. Jiménez Soriano Y, Bagan JV. Bisphosphonates, as a new cause of ruginduced jaw osreonecrosis: an update. Med Oral Patol Oral Cir Bucal 2005 Jul 1; 10 (2): 88-91.